MRNYYieldMax MRNA Option Income Strategy ETF
Seeks current income and exposure to the share price of Moderna, Inc. (MRNA).
By YieldMax ETFs · Launched 2023
Annual Cost
1.00%
#5,354 of 6,035 · expensive
Fund Size
$132M
#2,829 of 6,035 · mid-size
Return (1Y)
+58.9%
Track Record
2 years
#3,188 of 6,035 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$16,845+68.4%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
AlternativeStrategy
Option income
Holdings
By weightConcentration
single-stock exposure — holdings shown are derivatives collateral, not the fund's position
TREASURY BILL
27.0%
TREASURY BILL
24.8%
TREASURY BILL
22.1%
TREASURY BILL
12.1%
TREASURY BILL
12.0%
First American Government Obli
6.3%
N/A
3.2%
N/A
0.1%
N/A
0.0%
N/A
0.0%
Asset allocation
Stocks
61.7%
Bonds
40.0%
Other
0.3%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
60.2%High
Year-on-year price swings
Max drawdown
-82.2%Severe
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks current income and exposure to the share price of Moderna, Inc. (MRNA).
- Strategy
- Actively managed ETF that seeks current income through a synthetic covered call strategy on MRNA, generating options premiums while providing indirect exposure to MRNA's price returns. The strategy may limit potential gains but aims to capture a portion of MRNA's appreciation.
- Inception date
- October 23, 2023
- Fund family
- YieldMax ETFs
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save MRNY to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-17